etidronic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
calcium metabolism regulator, pharmaceutical aid	1098	2809-21-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: etidronic acid ethidronate ethydronate etidronate hydroxyethanediphosphonic acid oxyethylidenediphosphonic acid etidronate disodium	A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover. Molecular weight: 206.03 Formula: C2H8O7P2 CLOGP: -0.70 LIPINSKI: 0 HAC: 7 HDO: 5 TPSA: 135.29 ALOGS: -1.25 ROTB: 2 Status: OFM Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

etidronic acid
ethidronate
ethydronate
etidronate
hydroxyethanediphosphonic acid
oxyethylidenediphosphonic acid
etidronate disodium

A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.

Molecular weight: 206.03
Formula: C2H8O7P2
CLOGP: -0.70
LIPINSKI: 0
HAC: 7
HDO: 5
TPSA: 135.29
ALOGS: -1.25
ROTB: 2

Status: OFM

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.40	g	O
1.50	g	P
0.40	g	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	97.07 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
EoM (Fraction excreted unchanged in urine)	50 %	Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability)	5 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI

Showing 1 to 4 of 4 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Sept. 1, 1977	FDA	PROCTER AND GAMBLE

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Venous pressure jugular increased	104.71	54.89	16	924	561	63487521
Kyphosis	93.29	54.89	18	922	2522	63485560
Rectal prolapse	84.98	54.89	16	924	1967	63486115
Bundle branch block left	69.82	54.89	17	923	7042	63481040
Atypical femur fracture	63.79	54.89	15	925	5357	63482725
Upper-airway cough syndrome	57.11	54.89	16	924	11402	63476680
Blood test abnormal	56.43	54.89	17	923	15612	63472470

Showing 1 to 7 of 7 entries

Previous1Next

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Venous pressure jugular increased	94.39	53.66	16	953	1324	79742095
Kyphosis	89.49	53.66	17	952	2674	79740745
Rectal prolapse	86.63	53.66	16	953	2162	79741257
Atypical femur fracture	84.01	53.66	18	951	5171	79738248
Bundle branch block left	64.89	53.66	17	952	11496	79731923
Upper-airway cough syndrome	59.86	53.66	16	953	11677	79731742
Blood test abnormal	57.64	53.66	17	952	17693	79725726

Showing 1 to 7 of 7 entries

Previous1Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	M05BA01	MUSCULO-SKELETAL SYSTEM DRUGS FOR TREATMENT OF BONE DISEASES DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION Bisphosphonates
ATC	M05BB01	MUSCULO-SKELETAL SYSTEM DRUGS FOR TREATMENT OF BONE DISEASES DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION Bisphosphonates, combinations
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:38161	Chelating agent
CHEBI has role	CHEBI:50646	antiosteoporotic
FDA CS	M0006519	Diphosphonates
FDA EPC	N0000175579	Bisphosphonate
MeSH PA	D050071	Bone Density Conservation Agents

Showing 1 to 8 of 8 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Osteitis deformans	indication	2089002	DOID:5408
Humoral hypercalcemia of malignancy	indication	47709007
Heterotopic ossification	indication	128491006
Prevention of Glucocorticoid-Induced Osteoporosis	off-label use
Gastritis	contraindication	4556007	DOID:4029
Hypocalcemia	contraindication	5291005
Peptic ulcer	contraindication	13200003	DOID:750
Esophagitis	contraindication	16761005	DOID:11963
Hyperphosphatemia	contraindication	20165001	DOID:0050459
Swallowing painful	contraindication	30233002

Showing 1 to 10 of 29 entries

Previous1 2 3Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Show entries

Search:

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	1.29	acidic
pKa2	5.36	acidic
pKa3	6.35	acidic
pKa4	10.42	acidic
pKa5	12.86	acidic

Showing 1 to 5 of 5 entries

Previous1Next

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Type IV secretion-like conjugative transfer relaxase protein TraI	Unclassified		B1LRJ1_ECOSM		Ki	8.52		CHEMBL

Showing 1 to 1 of 1 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
911	PDB_CHEM_ID
002143	NDDF
004883	NDDF
1356715	RXNORM
2758	INN_ID
3305	PUBCHEM_CID
372908005	SNOMEDCT_US
387581008	SNOMEDCT_US
4018878	VANDF
4019753	VANDF

Showing 1 to 10 of 26 entries

Previous1 2 3Next

Pharmaceutical products:

None